Zapytanie ofertowe / Request for quotations
24 października 2016r.
Zapytanie ofertowe: stanowisko „Manager ds. rozwoju leku” w projekcie 3/1.1.1/2016.


The latest invention of GeneaMed is the use of dendrimer-based nanoparticles in the treatment of CLL.
Until now dendrimers have been used as drug delivery carriers. Our discovery indicates that maltotriose modification of these nanomolecules gives them a new value: they become an active substance – the drug itself. The nanoparticle prepared in such a way can cause the death of leukemic cells while not damaging healthy blood cells. The studies with the use of 4th generation-modified dendrimers have shown that they trigger apoptotis in leukemic cells which is impaired, thus reducing the number of leukemic cells. In addition, those glycodendrimers show no toxicity to other blood components (red blood cells and pellets), allowing an effective biodistribution and an efficient specificity. We’ve obtained positive results on CLL cells from patients and on customer cell lines in-vitro. GeneaMed is now conducting pre-clinical testing of patented and other new drug candidates. 

Our invention won the Gold Medal at the International Invention Exhibition „Concours Lépine 2013” in Paris organized by „Association des inventeurs et Fabricants Français”


GeneaMed has an exclusive right for two international patent applications:

• WO 2014088435 A1for dendrimer PPI-G4-OS-Mal-III,
• WO 2014088434 A1 for dendrimer PPI-G4-DS-Mal-III,

concerning the application of maltotriose-coated 4th generation polypropyleneimine dendrimers for treating neoplastic proliferative diseases, particularly chronic lymphocytic leukemia (CLL).



GeneaMed is a fusion of ideas, creativity and years of experience in the treatment and diagnosis of blood proliferative diseases.
The company develops innovative therapeutics for severe neoplastic proliferative diseases, particularly chronic lymphocytic leukemia (CLL). GeneaMed has two international patent applications and a new one will be filed soon.

The Management Board consists of qualified biotechnologists with over 10 years of experience in medical and genetic diagnostics along with a number of years of managerial experience. Founded in June 2015 as a university spin-off, GeneaMed was secured in private financing by INNOventure Fund from Poland. The main stakeholders are the Technology Accelerator the Foundation of the University of Lodz and the INNOventure Investment Fund from Poland.


If you are interested in cooperation with us please leave a message

GeneaMed LTD.
16/18 Kopcinskiego st, suite 904
90-232 Lodz, Poland

Mobile: +48 508-275-875


Send us a message


Spółka GeneaMed realizuje Projekt B+R o wartości 325.000 zł, w którym wkład z Funduszy Europejskich stanowi 80% tej kwoty. Wsparcie na realizację projektu zostało pozyskane w ramach projektu grantowego „Fundusz zalążkowy INNOventure jako kluczowy element krakowskiego ekosystemu wsparcia projektów badawczo-rozwojowych w obszarze innowacyjnych technologii i procesów przemysłowych” współfinansowanego ze środków Europejskiego Funduszu Rozwoju Regionalnego w ramach Programu Operacyjnego Inteligentny Rozwój Działanie 1.3: Prace B+R finansowane z udziałem funduszy kapitałowych Poddziałanie 1.3.1: Wsparcie projektów badawczo-rozwojowych w fazie preseed przez fundusze typu proof of concept – BRIdge Alfa.